SCHEMBL714847

SCHEMBL714847

Cc1ccc(S(=O)(=O)N/N=C/c2ccccc2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 9/20 0.70
ALDH1A1 P00352 9/20 0.70
MEN1 O00255 8/20 0.70
TDP1 Q9NUW8 4/20 0.70
KDM4E B2RXH2 2/20 0.69
LMNA P02545 4/20 0.65
RECQL P46063 3/20 0.62
POLB P06746 1/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
MAPT P10636 4/20 0.59
PKM P14618 1/20 0.59
NPSR1 Q6W5P4 1/20 0.59
GAA P10253 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
HTT P42858 1/20 0.58
RRM1 P23921 1/20 0.58
CYP1A2 P05177 2/20 0.57
CYP2C9 P11712 2/20 0.57
CYP2C19 P33261 2/20 0.57
CYP3A4 P08684 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL714848 1.00 KMT2A (0.70) KMT2AALDH1A1MEN1TDP1KDM4E
SCHEMBL6638949 1.00 KMT2A (0.70) KMT2AALDH1A1MEN1TDP1KDM4E
SCHEMBL7001854 0.98 KMT2A (0.68) KMT2AALDH1A1MEN1TDP1KDM4E
SCHEMBL7001853 0.98 KMT2A (0.68) KMT2AALDH1A1MEN1TDP1KDM4E
SCHEMBL28665880 0.94 KMT2A (0.71) KMT2AALDH1A1MEN1TDP1KDM4E
SCHEMBL28665881 0.94 KMT2A (0.71) KMT2AALDH1A1MEN1TDP1KDM4E
SCHEMBL27596882 0.94 KMT2A (0.72) KMT2AALDH1A1MEN1TDP1KDM4E
SCHEMBL18804653 0.94 KMT2A (0.72) KMT2AALDH1A1MEN1TDP1KDM4E
Fluorobenzene SCHEMBL28187017 0.93 KMT2A (0.72) KMT2AALDH1A1MEN1TDP1KDM4E
SCHEMBL25063711 0.92 KMT2A (0.80) KMT2AALDH1A1MEN1TDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122039073-A Preparation method of selenosulfonate derivative 宁夏医科大学 2026-05-15 CN disclosed
EP-4605247-A1 ELASTOMERIC COMPOSITIONS FOR TYRES COMPRISING NNEEWW CROSS-LINKING FUNCTIONALISING AGENTS, ELASTOMERIC COMPOUNDS AND TYRES COMPRISING THEM Pirelli Tyre S.p.A. (IT) 2025-08-27 EP disclosed
EP-3965738-B1 METHOD FOR PRODUCTION OF LIPOSOMES UNIV DO MINHO (PT) 2025-08-06 EP disclosed
WO-2025136936-A1 AGONISTS OF TREM2 ACTIVITY MERCK SHARP & DOHME LLC (US) 2025-06-26 WO disclosed
WO-2024084386-A9 ELASTOMERIC COMPOSITIONS FOR TYRES COMPRISING NNEEWW CROSS-LINKING FUNCTIONALISING AGENTS, ELASTOMERIC COMPOUNDS AND TYRES COMPRISING THEM PIRELLI TYRE S.P.A. (IT) 2025-06-12 WO disclosed
US-20220241203-A1 METHOD FOR PRODUCTION OF LIPOSOMES UNIVERSIDADE DO MINHO (PT) 2022-08-04 US disclosed
CN-113816906-A Synthesis method of novel azepane 成都理工大学 2021-12-21 CN disclosed
WO-2021012264-A1 TRIAZOLE SULFONAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 东莞市东阳光农药研发有限公司 2021-01-28 WO disclosed
WO-2017183043-A1 NOVEL PROCESS FOR THE PREPARATION OF TAVABOROLE, ITS NOVEL POLYMORPHIC FORMS AND THE POLYMORPHS THEREOF BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) 2017-10-26 WO disclosed
US-8124578-B2 Use of dynamic mixtures for a controlled release of fragrances FIRMENICH SA (CH) 2012-02-28 US disclosed
EP-1478437-A1 ACC INHIBITORS Pfizer Products Inc. (US) 2004-11-24 EP disclosed
US-20030187254-A1 Acetyl-CoA carboxylase inhibitors PFIZER INC. 2003-10-02 US disclosed
WO-2003072197-A1 ACC INHIBITORS PFIZER PRODUCTS INC. (US) 2003-09-04 WO disclosed
US-6313290-B1 Azolobenzazepine derivatives and compositions and method of use thereof ZENECA LIMITED (GB) 2001-11-06 US disclosed
US-6124281-A TREATING STROKES ZENECA LIMITED (GB) 2000-09-26 US disclosed
US-5994552-A Process for the production of substituted thiazoline-dioxetan substrates and use thereof ROCHE DIAGNOSTICS GMBH (DE) 1999-11-30 US disclosed
EP-0888350-A1 AZOLOBENZAZEPINE DERIVATIVES AS NEUROLOGICALLY ACTIVE AGENTS ZENECA LIMITED (GB) 1999-01-07 EP disclosed
US-5712106-A Process for the production of substituted thiazolin-dioxetan substrates and use thereof BOEHRINGER MANNHEIM GMBH (DE) 1998-01-27 US disclosed
WO-1997032883-A1 AZOLOBENZAZEPINE DERIVATIVES AS NEUROLOGICALLY ACTIVE AGENTS ZENECA LIMITED (GB) 1997-09-12 WO disclosed
US-5455357-A Substituted thiazoline-dioxetan substrates, process for the production and use BOEHRINGER MANNHEIM GMBH (DE) 1995-10-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187254-A1 Acetyl-CoA carboxylase inhibitors ACACA, ACACB, ACAT1 KMT2A 2346/4885ALDH1A1 654/4885MEN1 3712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.